Cinnamaldehyde Regulates the EMT Process and Drug Resistance of Gastric Cancer Through FSTL3-Mediated Cytoskeletal...

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Cinnamaldehyde (CA) exhibits anti-tumor properties, but its mechanism in gastric cancer (GC) is not fully understood.
• Investigating CA's role in GC proliferation, migration, epithelial-mesenchymal transition (EMT), and drug resistance is crucial.
• The potential involvement of follistatin-like 3 (FSTL3) in CA's anti-GC effects requires elucidation.

Purpose of the Study:

• To determine the effects of Cinnamaldehyde (CA) on gastric cancer (GC) cell proliferation, migration, EMT, and drug resistance.
• To explore the molecular mechanism underlying CA's anti-tumor activity in GC, focusing on follistatin-like 3 (FSTL3).
• To evaluate the therapeutic potential of targeting FSTL3 in GC treatment.

Main Methods:

• In vitro studies involving CA treatment of GC cells to assess proliferation, migration, EMT markers, and FSTL3 expression.
• In vivo experiments using GC xenograft and liver metastasis models to evaluate CA's anti-tumor and anti-metastatic efficacy.
• Analysis of FSTL3 expression, cytoskeleton dynamics, EMT-related proteins, and TGF-β/SMAD signaling pathway.

Main Results:

• Cinnamaldehyde (CA) significantly inhibited GC cell proliferation and migration in vitro.
• CA treatment downregulated follistatin-like 3 (FSTL3) expression and altered cytoskeleton organization in GC cells.
• In vivo studies confirmed that CA suppressed tumor growth, invasion, and metastasis by modulating EMT and TGF-β/SMAD signaling via FSTL3.

Conclusions:

• The anti-tumor effects of Cinnamaldehyde (CA) in gastric cancer (GC) are primarily mediated by the downregulation of follistatin-like 3 (FSTL3).
• FSTL3 plays a critical role in mediating CA's inhibition of GC cell proliferation, migration, and metastasis.
• Targeting FSTL3 presents a promising therapeutic strategy for GC treatment and overcoming drug resistance.